MDACC Study Summary 2006-0198

Study Summary
No. 2006-0198:.......Unspecified......Patricia A. Parker......Community Oncology

Study Summary Title



Study Summary Number:	2006-0198

Study Title:	CAM Use and Cancer

Physician

New Patient Referral



Name:	Patricia A. Parker	Patients Call:	800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Dept:	Community Oncology	Referring MD Call:	800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Phone:	713-563-0276 Contact us about clinical trials

General Information



Disease Group:	Unspecified	Supported By:	NCI

Phase of Study:	Phase III	Return Visit:	N/A

Treatment Agents:	None	Home Care:	N/A

Treatment Loc:	Only at Community Programs (CCOP/Network)

Estimated Length of Stay in Houston:	N/A


Description/ Intervention:	The goal of this study is to collect information regarding perceptions, knowledge of and discussions about complementary and alternative medicine (CAM) between you and your patients. This information will be collected using questionnaires given to you and your patients at specific time points.

Study Objectives / Outcomes

1.1 Primary Objective

Examine the efficacy of an educational intervention designed to increase the frequency with which nurses/healthcare providers (Providers) ask their patients about Complimentary and Alternative Medicine (CAM) usage.

1.2 Secondary Objectives

1.2.1 Examine frequency of CAM use and referral for CAM use in

nurses/healthcare providers.

1.2.2 Evaluate whether personal CAM use among

nurses/healthcare providers

is related to frequency of asking patients about CAM.

1.2.3 Assess the frequency and type of CAM use among patients diagnosed with cancer.

Study Status Information



Study Activation / Registration Date:

IRB Review and Approval Date:	06/04/2008

Study Type:	Behavioral

Recruitment Status:	Open

Projected Accrual:	1360

Enrollment Eligibility

If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.

Inclusion Criteria:

1) Providers who have regular contact by initially talking with oncology patients, taking their histories and conveying pertinent information to their physician at a participating Community Clinical Oncology Program (CCOP) site.

2) Providers must sign a written informed consent document.

3) Patients must have a current diagnosis of cancer including amyloidosis.

4) Patients must be at least one week post-diagnosis and no longer than six months post-treatment.

5) Patients must have the ability to understand and sign a written informed consent document.

Exclusion Criteria:

1) Providers who are not actively seeing patients at a participating CCOP site.

2) Providers must not be employed at more than one participating site and must not be temporary employees.

3) Patients with an inability to speak or read English.

4) Patients who have previously participated in this study at an earlier assessment.

Links

Registration Number: NCT00608933
Study Information on Clinical Trials Registry (clinicaltrials.gov)